International Society on Hypertension in Blacks

ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension

Retrieved on: 
Friday, July 14, 2023
Health, FDA, Medical Devices, Health Technology, Pharmaceutical, Cardiology, Biotechnology, Blood pressure, CE, European Renal Association, Food, ReCore, SOLO, RDN, ERA, Journal, PMA, Patient, European Society for Medical Oncology, International Society on Hypertension in Blacks, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, International Society, Pharmaceutical industry, Medicine, Hypertension

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.

Key Points: 
  • ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.
  • The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.
  • Current rates of treatment and control of hypertension remain suboptimal, and the ESH guidelines assist clinicians and patients in achieving the goal of better health.
  • “Recommendation of renal denervation by the recently published European Society of Hypertension (ESH) 2023 Guidelines is a significant milestone for the field of arterial hypertension management.

New European Hypertension Guidelines Pave the Way for Greater Access to High Blood Pressure Procedure

Retrieved on: 
Wednesday, July 12, 2023
Blood pressure, Exercise, International Society on Hypertension in Blacks, Diet, Chronic kidney disease, European Renal Association, Stroke, Splenic infarction, Citizens for Europe, European Society of Cardiology, RDN, ISH, ERA, Hypertension, Patient, Risk, European Society for Medical Oncology, International Society, Pharmaceutical industry

BRUSSELS, July 12, 2023 /PRNewswire/ -- Citizens of Europe at risk for heart attacks, stroke and chronic kidney disease due to uncontrolled high blood pressure will benefit from new expert treatment guidelines that recognize the benefits of renal denervation, or RDN.  

Key Points: 
  • Last month the European Society of Hypertension, or ESH, updated its treatment guidance to include RDN as a recommended treatment option for patients who need arterial hypertension management.
  • Inclusion of RDN in the treatment guidelines means patients who struggle to lower their blood pressure through diet, exercise or antihypertensive medications will now have a safe, effective adjunctive treatment option.
  • The guidelines were also endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).
  • More than 150 million Europeans currently have hypertension, according to the European Society of Cardiology, and more than 40% of them can't adequately manage their blood pressure.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

World's first automated 24/7 blood pressure monitor comes to the USA

Retrieved on: 
Tuesday, January 4, 2022
CES, Hypertension, Risk, INTRODUCTION, FDA, International Society on Hypertension in Blacks, PPG, VIA, Swiss Center for Electronics and Microtechnology, Multimedia, Continuous noninvasive arterial pressure, CSEM, Hospital, Time, Blood pressure, Diagnosis, Photoplethysmogram, Clinical professor, Faculty, Stroke, CE marking, Algorithm, Cardiology, Trust, Research, The Green Album, Program, Mayo Clinic, Draper Esprit, Sleep, International Society, Wrist, Cone Health Women's Hospital, View, Artery, Physician, Electronics, Patient, Sphygmomanometer, Global health, Sale, Medical device, Pharmaceutical industry, Tutoring, Microtechnology, BWH

In the United States, nearly 50% of adults, about 116 million people, have high blood pressure.

Key Points: 
  • In the United States, nearly 50% of adults, about 116 million people, have high blood pressure.
  • Yet current measurement devices only capture a brief snapshot of overall blood pressure, and they are burdensome to use.
  • Aktiia'sOptical Blood Pressure Monitoring (OBPM) algorithms leverage optical sensors worn on the wrist and provide blood pressure values using photoplethysmography (PPG) toanalyzethe changing diameter of the arteries occurring at each heartbeat.
  • Founded in Switzerland in May 2018, Aktiia'steam has some of the world's leading scientific and technical experts in optical blood pressure monitoring.

Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan

Retrieved on: 
Wednesday, December 1, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Fitness & Nutrition, Clinical Trials, Research, Volunteering, Degenerative disease, INSIGHT, Blood pressure, Population, Hypertension, Research and development, Mercury (element), International Society on Hypertension in Blacks, Development, European Society of Cardiology, Protocol, Cardiovascular disease, International Society, Pharmaceutical industry

It will include two groups: a TOTUM854 group with a dose of 3.7 g/day and a placebo group.

Key Points: 
  • It will include two groups: a TOTUM854 group with a dose of 3.7 g/day and a placebo group.
  • Its main objective will be to reduce systolic blood pressure in the TOTUM854 group after 3 months of supplementation versus the placebo group.
  • Its main objective will be to reduce systolic blood pressure in the TOTUM854 group after 3 months of supplementation versus the placebo group.
  • It will thus assess the effect of a reduced dose of TOTUM854 (2.6 g/day) on blood pressure.

Aktiia® launches into healthcare market with $17.5M investment for its world-first 24-7 Blood Pressure Monitoring System

Retrieved on: 
Wednesday, November 3, 2021
Sola, Sleep, Death, Diagnosis, Technology, Photoplethysmogram, Electronics, Algorithm, Wrist, Patient, International Society, PPG, White coat hypertension, CSEM, NHS, Blood pressure, Handbook, Silicon, International Society on Hypertension in Blacks, Ownership, Draper Esprit, Scientific Reports, CTO, Artery, Swiss Center for Electronics and Microtechnology, Physician, Pharmaceutical industry, Medical device

This Series A will be used to expand its offer to healthcare systems within these geographies as well as moving into new territories.

Key Points: 
  • This Series A will be used to expand its offer to healthcare systems within these geographies as well as moving into new territories.
  • In addition to endorsement by leading clinicians in hypertension management, Aktiia is now also an official partner of the International Society of Hypertension .
  • "Thisisan indisputable game changer inenabling abetter understanding of our patients' blood pressure patternsand how to treat themon apersonalizedbasis."
  • AboutAktiia:Founded in Switzerland in May 2018, Aktiia's team has some of the world's leading scientific and technical experts in optical blood pressure monitoring, including CTO, Dr. Josep Sola , a pioneer in cuffless blood pressure monitoring and editor of "The Handbook of Cuffless Blood Pressure Monitoring."

Valbiotis Reviews Its Activities and Publishes Its Financial Report for the First Half of 2021

Retrieved on: 
Thursday, September 30, 2021
Health, Diabetes, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Genta (company), AHA, Patent, Marketing, Partnership, Université Laval, Hypercholesterolemia, Nutrient, ESH, Ipsen, Risk, Solution, Degenerative disease, AFNOR, Board of directors, McNeil Consumer Healthcare, American Journal, INAF, Lists of diseases, Population, Certification, American Heart Association, Adult, HEART, International Society, Board, International Society on Hypertension in Blacks, Canadian International Council, NASH, Obesity, Company, Program, Cardiovascular disease, Prevalence, Production, Trial of the century, European Society of Neurogastroenterology and Motility, Overweight, IFRS, ISH, Statutory auditor, Metabolism, Director, Prediabetes, Acceleration, Chief business officer, Discovery, Pharmaceutical industry, Medical device, Animal, Dietary supplement

In addition to achieving new scientific milestones and strengthening our organization, we also secured our financial resources on a long-term basis.

Key Points: 
  • In addition to achieving new scientific milestones and strengthening our organization, we also secured our financial resources on a long-term basis.
  • Announced in May 2021 ( press release of May 19, 2021 ), this patent grants broad protection for the composition and use of this substance.
  • Financial information for the first half of 2021: a secure long-term financial position
    The Company's half-yearly financial statements, prepared in accordance with IFRS, were approved by the Board of Directors on September 27, 2021.
  • They have been subject to a limited review by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com (investors section).